| ULTRAGENYX PHARM. DL-,001 |
| USA |
| Gesundheit |
| US90400D1081 / A1XCY0 |
| UP0 (Frankfurt) / RARE (NASDAQ) |
| FRA:UP0, ETR:UP0, UP0:GR, NASDAQ:RARE |
| - |
| https://www.ultragenyx.co.. |
|
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious rare and ultra-rare genetic diseases. Its current portfolio includes Crysvita, an antibody treatment for X-linked hypophosph..
>Volltext.. |
| 1430.11 Mio. EUR |
| 2221.55 Mio. EUR |
| 638.02 Mio. EUR |
| -440.96 Mio. EUR |
| -521.86 Mio. EUR |
| -5.2 EUR |
| 1069.69 Mio. EUR |
| 119.25 Mio. EUR |
| -431.84 Mio. EUR |
| 0.86 |
| 21.2% |
| -13.5% |
| - |
| - |
| - |
| ULTRAGENYX |
| 04.11.26 |
|
||||
|